Objective. To evaluate the alterations of Global longitudinsl strain (GLS) and it’s value for prediction cardiotoxicity low to moderate cumulative doses anthracyclines. Methods. Forty-nine women 50 ± 10 years old with breast cancer, treated anthracyclines (cumulative dose 251 60 mg/m2) were enrolled in study. Echocardiography GLS measurement was performed at baseline, end anthracycline treatmen...

In the accompanying paper (Davies, K. J. A., and Doroshow, J. A. (1986) J. Biol. Chern. 261, 30603067), we have demonstrated that anthracycline antibiotics are reduced to the semiquinone form at Complex I of the mitochondrial electron transport chain. In the experiments presented in this study we examined the effects of doxorubicin (Adriamycin), daunorubicin, and related quinonoid anticancer ag...

BACKGROUND Chemotherapy with anthracyclines and trastuzumab can cause cardiotoxicity. Alteration of cardiac adrenergic function assessed by metaiodobenzylguanidine labeled with iodine-123 (123I-mIBG) seems to precede the drop in left ventricular ejection fraction. OBJECTIVE To evaluate and to compare the presence of cardiovascular abnormalities among patients with breast cancer undergoing che...

C ontinual advances in antineoplastic therapies have produced better cancer outcomes with 13.7 million cancer survivors in the United States in 2013 1. However, a significant number of survivors may develop cardiac disease as a result of cancer treatment, whether chemotherapy, radiation, or a combination of both. 2 Although radiation can cause significant heart disease 3 both alone and with che...

Aim . To evaluate the effectiveness of morpholinium-methyl-triazolyl-thioacetate (thiotriazoline) as a cardioprotector in patients with non-Hodgkin’s lymphomas who received chemotherapy inclusion anthracyclines. Material and methods Fifty were examined on background antitumor therapy. The divided into 2 following groups: group 1 (n=27) — standard chemotherapy; (n=23) thiotriazoline cardioprotec...

Abstract Background Cardiotoxicity remains a dreaded complication for patients undergoing chemotherapy with human epidermal growth factor (HER)-2 receptor antagonists and anthracyclines. Though many studies have looked at racial disparities in heart failure patients, minimal data is present the cardio-oncology population. Methods We queried echocardiogram database safety net hospital, defined b...

BACKGROUND Exposure to anthracyclines (ANT) during childhood represents a high risk for development of late cardiotoxicity. Cardiotoxicity is usually detected only when clinical symptoms or progressive cardiac dysfunction have already occurred. Early detection of cardiotoxicity may lead to better therapeutic outcome. N-terminal pro-brain natriuretic peptide (NTproBNP) has been hypothesized to r...

Preclinical and clinical studies suggest that anthracycline-induced cardiotoxicity can be prevented by administering coenzyme Q10 during cancer chemotherapy that includes drugs such as doxorubicin and daunorubicin. Studies further suggest that coenzyme Q10 does not interfere with the antineoplastic action of anthracyclines and might even enhance their anticancer effects. Preventing cardiotoxici...